Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cantor Fitzgerald Reiterates Overweight on Insmed, Maintains $46 Price Target

Author: Benzinga Newsdesk | September 19, 2023 09:12am
Cantor Fitzgerald analyst Jennifer Kim reiterates Insmed (NASDAQ:INSM) with a Overweight and maintains $46 price target.

Posted In: INSM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist